SBIR Phase I: Automated One-Hour Testing for Bacteremia and Antibiotic Sensitivity

SBIR 第一阶段：一小时自动检测菌血症和抗生素敏感性

• 批准号: 2304069
• 负责人: Mustafa Al-Adhami
• 金额: $ 27.46万
• 依托单位: ASTEK DIAGNOSTICS LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2304069&HistoricalAwards=false
• 关键词: SBIR; Phase; Automated; Hour; Testing

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve early detection and clinical management of bacteremia in patients suspected of bacterial sepsis. Over 250,000 patients die of sepsis each year in the U.S., which results in hospitalization costs exceeding $20 billion. A sepsis patient’s risk of death has been demonstrated to increase by 4-7% per hour, where timely administration of appropriate antibiotics is expected to improve patient survival. Unfortunately, the standard of care approach for determining antibiotic susceptibility requires overnight culturing that can take a day or more. Currently, broad spectrum antibiotics are administered within the first hour of treatment with the hope that the pathogen will be susceptible, while waiting for antibiotic susceptibility results. The growing landscape of antibiotic resistance severely undermines the efficacy of the standard approach, as many pathogens are increasingly resistant to broad-spectrum antibiotics. This project seeks to advance development of a novel optical approach for determining antibiotic susceptibility results within 1 hour to support the use of appropriate antibiotics, which has significant potential to improve patient mortality outcomes and reduce hospitalization costs.This Small Business Innovation Research (SBIR) Phase I project involves an optical technology for the rapid determination of antibiotic susceptibility results from a blood sample for patients suspected of bacteremia. The product uses an assay for assessment of bacterial metabolism, where a blood specimen may be cultured with and without antibiotics to determine antibiotic susceptibility. Advancements in the assay and microfluidics enable delivery of antibiotic susceptibility results within one hour. This timeframe would enable clinicians to use antibiotics that are targeted to the patient’s specific bacterial pathogen significantly earlier, which is expected to improve patient outcomes. The goal of this project will be to rigorously demonstrate the proof-of-concept and reproducibility of the technology.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业创新研究(SBIR)第一阶段项目的更广泛的影响/商业潜力是改善对疑似细菌性败血症患者的菌血症的早期发现和临床管理。在美国，每年有超过25万名患者死于脓毒症，这导致住院费用超过200亿美元。败血症患者的死亡风险已被证明每小时增加4-7%，及时给予适当的抗生素有望提高患者的存活率。不幸的是，确定抗生素敏感性的标准护理方法需要通宵培养，可能需要一天或更长时间。目前，广谱抗生素是在治疗的第一个小时内给予的，希望在等待抗生素敏感性结果的同时使病原体变得敏感。越来越多的抗生素耐药性严重破坏了标准方法的有效性，因为许多病原体对广谱抗生素的耐药性越来越强。该项目旨在推进一种新的光学方法的开发，以在1小时内确定抗生素敏感性结果，以支持适当抗生素的使用，这具有改善患者死亡率和降低住院成本的巨大潜力。这项小型企业创新研究(SBIR)第一阶段项目涉及一种光学技术，用于从疑似菌血症患者的血液样本中快速确定抗生素敏感性结果。该产品使用一种用于评估细菌新陈代谢的测试，其中血液样本可以在含有和不含有抗生素的情况下进行培养，以确定抗生素的敏感性。检测和微流控技术的进步使抗生素敏感性结果能够在一小时内公布。这一时间框架将使临床医生能够更早地使用针对患者特定细菌病原体的抗生素，这有望改善患者的预后。该项目的目标将是严格证明该技术的概念验证和重现性。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。